Movement Alert｜Twist Bioscience Corp Rises 6.12% in Regular Trading, Momentum Builds on UBS Coverage Initiation and AI Partnership Tailwinds

Market Focus

Yesterday

On September 14, Twist Bioscience Corp rose 6.12% in regular trading, trading at $134.60 USD/share, with turnover of $103 million.

The rally appears to be fueled by a combination of recent positive catalysts. UBS initiated coverage on Twist Bioscience on September 9 with a Neutral rating and a $144 price target, implying significant upside from the stock's prior trading levels near $127. The $144 target stands notably above the consensus mean price target of $87.56, signaling a re-rating of the company's valuation among institutional analysts.

Adding to the bullish momentum, Twist Bioscience was selected by Anthropic in August as an independent evaluator for a multi-arm protein design project leveraging artificial intelligence, a development that previously drove a 17% single-day surge. The company also issued upbeat fiscal Q4 revenue guidance of $123 million to $124 million, well above the FactSet consensus estimate of $117.4 million, reinforcing confidence in its growth trajectory.

Within the Biotechnology sector, the broader group traded higher. Among individual stocks, Moderna rose 2.15%, AbbVie rose 1.94%, Gilead Sciences rose 1.36%, Regeneron Pharmaceuticals rose 1.27%, and Amgen rose 0.75%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/news/1186866029"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1186866029\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1186866029?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 00:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186866029","market":"us","top_or_hot":-1,"title":"Movement Alert｜Twist Bioscience Corp Rises 6.12% in Regular Trading, Momentum Builds on UBS Coverage Initiation and AI Partnership Tailwinds","media":"Market Focus","content":"<p><p>On September 14, Twist Bioscience Corp rose 6.12% in regular trading, trading at $134.60 USD/share, with turnover of $103 million.</p><p>The rally appears to be fueled by a combination of recent positive catalysts. UBS initiated coverage on Twist Bioscience on September 9 with a Neutral rating and a $144 price target, implying significant upside from the stock's prior trading levels near $127. The $144 target stands notably above the consensus mean price target of $87.56, signaling a re-rating of the company's valuation among institutional analysts.</p><p>Adding to the bullish momentum, Twist Bioscience was selected by Anthropic in August as an independent evaluator for a multi-arm protein design project leveraging artificial intelligence, a development that previously drove a 17% single-day surge. The company also issued upbeat fiscal Q4 revenue guidance of $123 million to $124 million, well above the FactSet consensus estimate of $117.4 million, reinforcing confidence in its growth trajectory.</p><p>Within the Biotechnology sector, the broader group traded higher. Among individual stocks, Moderna rose 2.15%, AbbVie rose 1.94%, Gilead Sciences rose 1.36%, Regeneron Pharmaceuticals rose 1.27%, and Amgen rose 0.75%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Twist Bioscience Corp Rises 6.12% in Regular Trading, Momentum Builds on UBS Coverage Initiation and AI Partnership Tailwinds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Twist Bioscience Corp Rises 6.12% in Regular Trading, Momentum Builds on UBS Coverage Initiation and AI Partnership Tailwinds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-15 00:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 14, Twist Bioscience Corp rose 6.12% in regular trading, trading at $134.60 USD/share, with turnover of $103 million.</p><p>The rally appears to be fueled by a combination of recent positive catalysts. UBS initiated coverage on Twist Bioscience on September 9 with a Neutral rating and a $144 price target, implying significant upside from the stock's prior trading levels near $127. The $144 target stands notably above the consensus mean price target of $87.56, signaling a re-rating of the company's valuation among institutional analysts.</p><p>Adding to the bullish momentum, Twist Bioscience was selected by Anthropic in August as an independent evaluator for a multi-arm protein design project leveraging artificial intelligence, a development that previously drove a 17% single-day surge. The company also issued upbeat fiscal Q4 revenue guidance of $123 million to $124 million, well above the FactSet consensus estimate of $117.4 million, reinforcing confidence in its growth trajectory.</p><p>Within the Biotechnology sector, the broader group traded higher. Among individual stocks, Moderna rose 2.15%, AbbVie rose 1.94%, Gilead Sciences rose 1.36%, Regeneron Pharmaceuticals rose 1.27%, and Amgen rose 0.75%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TWST","symbol_name":"Twist Bioscience Corp","start_time":0,"source_url":"","article_id":"1186866029","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186866029","pubTimestamp":1789402856,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 14, Twist Bioscience Corp rose 6.12% in regular trading, trading at $134.60 USD/share, with turnover of $103 million.The rally appears to be fueled by a combination of recent positive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TWST":"Twist Bioscience Corp"},"translate_title":"走势警报|Twist Bioscience Corp 在常规交易中上涨 6.12%，瑞银保险启动和人工智能合作伙伴关系的推动势头增强","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":1},"content_text":"On September 14, Twist Bioscience Corp rose 6.12% in regular trading, trading at $134.60 USD/share, with turnover of $103 million.The rally appears to be fueled by a combination of recent positive catalysts. UBS initiated coverage on Twist Bioscience on September 9 with a Neutral rating and a $144 price target, implying significant upside from the stock's prior trading levels near $127. The $144 target stands notably above the consensus mean price target of $87.56, signaling a re-rating of the company's valuation among institutional analysts.Adding to the bullish momentum, Twist Bioscience was selected by Anthropic in August as an independent evaluator for a multi-arm protein design project leveraging artificial intelligence, a development that previously drove a 17% single-day surge. The company also issued upbeat fiscal Q4 revenue guidance of $123 million to $124 million, well above the FactSet consensus estimate of $117.4 million, reinforcing confidence in its growth trajectory.Within the Biotechnology sector, the broader group traded higher. Among individual stocks, Moderna rose 2.15%, AbbVie rose 1.94%, Gilead Sciences rose 1.36%, Regeneron Pharmaceuticals rose 1.27%, and Amgen rose 0.75%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}